Artelo Biosciences (ARTL) Operating Leases (2021 - 2025)

Artelo Biosciences (ARTL) has reported Operating Leases for 5 consecutive years, with $29000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Operating Leases fell 57.97% year-over-year to $29000.0 in Q4 2025; TTM through Dec 2025 was $29000.0, a 57.97% decrease from a year earlier, with the FY2025 full-year figure at $29000.0, down 57.97% from the prior year.
• Operating Leases was $29000.0 for Q4 2025 at Artelo Biosciences, down from $40000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $96000.0 in Q1 2024 and troughed at $6000.0 in Q2 2023.
• A 5-year average of $50000.0 and a median of $50000.0 in 2022 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases tumbled 85.0% in 2023 and surged 1350.0% in 2024, its largest moves.
• Over 5 years, Operating Leases stood at $59000.0 in 2021, then tumbled by 61.02% to $23000.0 in 2022, then slumped by 73.91% to $6000.0 in 2023, then soared by 1050.0% to $69000.0 in 2024, then slumped by 57.97% to $29000.0 in 2025.
• The last three Operating Leases figures came in at $29000.0 (Q4 2025), $40000.0 (Q3 2025), and $51000.0 (Q2 2025), per Business Quant data.